BFRI News and Press, Biofrontera Inc. From 12/21/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re kicking off the day with a dive into the biggest pre-market stock movers for Tuesday! Source: ventdusud / Shutterstock.com Moving stocks this morning is Covid-19 antibody news, ear...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we’re diving into some top candidates! Source: Shutterstock We’re pulling our short stock data from Twi...

Gainers: Biofrontera (NASDAQ:BFRI) +26%, Gemini Therapeutics (NASDAQ:GMTX) +19%, Vir Biotechnology (NASDAQ:VIR) +14%, Mesoblast (NASDAQ:MESO) +14%, Tandem Diabetes Care (NASDAQ:TNDM) +10% Losers: Atai Life Sciences (NASDAQ:ATAI) -24%, Alzamend...

Following a loss of nearly a fifth of its market cap on Tuesday, Biofrontera (NASDAQ:BFRI) has recovered to add ~24.7% in the pre-market after Benchmark began its coverage with a Buy rating. The analyst Bruce Jackson has set the price target at $11 per share to imply a premium of 10...

Gemini Therapeutics (NASDAQ:GMTX) +34%. Galera Therapeutics (NASDAQ:GRTX) +25% raised to Buy at HC Wainwright, BTIG after avasopasem trial met primary endpoint. CMC Materials (NASDAQ:CCMP) +24% Entegris to acquire CMC Materials in a cash and stock transaction worth $6.5B. ...

Gainers: Galera Therapeutics (NASDAQ:GRTX) +116%, Alzamend Neuro (NASDAQ:ALZN) +18%, Soliton (NASDAQ:SOLY) +12%, Kiromic BioPharma (NASDAQ:KRBP) +6%, Biofrontera (NASDAQ:BFRI) +5%. Losers: Adagio Therapeutics (NASDAQ:ADGI) -78%, Adagio Th...

Gainers: Nuverra Environmental Solutions (NYSE:NES) +88%. Arena (NASDAQ:ARNA) +82%. BELLUS (NASDAQ:BLU) +56%. Foghorn Therapeutics (NASDAQ:FHTX) +43%. Petros Pharmaceuticals (NASDAQ:PTPI) +45%. Biofrontera (NASDAQ:BFRI) +29%. Mawson Infrastructure Group (OTCQB:MIGI) +17%. Reliance Global Grou...

Biofrontera (BFRI +18.6%) announces that the first subject has been enrolled in the Phase 2b study to evaluate the safety and efficacy of Ameluz in combination with the red-light lamp BF-RhodoLED for the treatment of moderate-to-severe acne with photodynamic therapy (Ameluz-PDT...

WOBURN, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) , a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the first subject has been enrolled in the Phase 2b study performed by Biofronter...